B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny

Clinical Immunology

Volumn 122, Issue 2, 2007, Pages 139-145

  Anolik, Jennifer H ^a   Friedberg, Jonathan W ^a   Zheng, Bo ^a   Barnard, Jennifer ^a   Owen, Teresa ^a   Cushing, Emily ^a   Kelly, Jennifer ^a   Milner, Eric C B ^a   Fisher, Richard I ^a   Sanz, Iñaki ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

B lymphocytes; Lymphoma; Rituximab; Transitional B cells

Indexed keywords

CD27 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; RITUXIMAB; VACCINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MALE; MEMORY CELL; NONHODGKIN LYMPHOMA; ONTOGENY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MALE; MIDDLE AGED;

EID: 33846104336     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.08.009     Document Type: Article

References (27)

1. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 8 (1994) 2457-2466
2. Looney R.J., Anolik J., and Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr. Opin. Rheumatol. 16 3 (2004) 180-185
3. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54 2 (2006) 613-620
4. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54 8 (2006) 2377-2386
5. Storek J., Ferrara S., Ku N., Giorgi J., Champlin R., and Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny?. Bone Marrow Transplant. 12 (1993) 387-398
6. Suzuki I., Milner E.C., Glas A.M., Hufnagle W.O., Rao S.P., Pfister L., et al. Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest. Blood 87 5 (1996) 1873-1880 (see comment)
7. Sale G.E., Alavaikko M., Schaefers K.M., and Mahan C.T. Abnormal CD4:CD8 ratios and delayed germinal center reconstitution in lymph nodes of human graft recipients with graft-versus-host disease (GVHD): an immunohistological study. Exp. Hematol. 20 8 (1992) 1017-1021
8. Avanzini M.A., Locatelli F., Dos Santos C., Maccario R., Lenta E., Oliveri M., et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp. Hematol. 33 4 (2005) 480-486
9. Hainsworth J.D., Litchy S., Shaffter D., Lackey V., Grimaldi M., and Greco F. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23 (2005) 1088-1095
10. Gordan L.N., Grow W.B., Pusateri A., Douglas V., Mendenhall N.P., and Lynch J.W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J. Clin. Oncol. 23 6 (2005) 1096-1102 (see comment)
11. McLaughlin P., Grillo-Lopez A., Link B., Levy R., Czuczman M., Williams M., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
12. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 2 (2005) 489-495
13. Hurvitz S., and Timmerman J. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphoma: a focus on FavId. Exp. Opin. Biol. Ther. 5 (2005) 841-852
14. Anolik J., Barnard J., Cappione A., Pugh-Bernard A., Felgar R., Looney J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3580-3590
15. Pugh-Bernard A.E., Silverman G.J., Cappione A.J., Villano M.E., Ryan D.H., Insel R.A., et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108 7 (2001) 1061-1070
16. Pascual V., Liu Y.J., Magalski A., de Bouteiller O., Banchereau J., and Capra J.D. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180 1 (1994) 329-339
17. Bornhorst J., Bjorgan M., Thoen J., Natvig J., and Thompson K. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167 (2001) 3610-3618
18. Sims G.P., Ettinger R., Shirota Y., Yarboro C.H., Illei G.G., and Lipsky P.E. Identification and characterization of circulating human transitional B cells. Blood 105 11 (2005) 4390-4398
19. Wirth S., and Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur. J. Immunol. 35 (2005) 3433-3441
20. Ghielmini M., Rufibach K., Salles G., Leoncini-Franscini L., Leger-Falandry C., Cogliatti S., et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 16 (2005) 1675-1682
21. Cuss A., Avery D., Cannons J., Yu L., Nichols K., Shaw P., et al. Expansion of functionally immature transitional B cells is associated with human immunodeficient states characterized by impaired humoral immunity. J. Immunol. 176 (2006) 1506-1516
22. Kruetzmann S., Rosado M.M., Weber H., Germing U., Tournilhac O., Peter H.H., et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197 7 (2003) 939-945
23. Gokmen E., Raaphorst F.M., Boldt D.H., and Teale J.M. Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization. Blood 92 8 (1998) 2802-2814
24. Horning S.J. Optimizing rituximab in B-cell lymphoma. J. Clin. Oncol. 23 6 (2005) 1056-1058 (comment)
25. Malaspina A., Moir S., Ho J., Wang W., Howell M.L., O'Shea M.A., et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl. Acad. Sci. U. S. A. 103 7 (2006) 2262-2267
26. J.W. Friedberg, Targeting CD20 in follicular NHL: unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. 2005.
27. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17 4 (1999) 1244